Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma: A multicenter retrospective cohort study

American Journal of Gastroenterology

Volumn 109, Issue 12, 2014, Pages 1891-1899

  Feng, Xiaobin ^a   Xu, Ruocai ^b   Du, Xilin ^c   Dou, Kefeng ^d   Qin, Xiao ^e   Xu, Jun ^f   Jia, Weidong ^g   Wang, Zhiming ^h   Zhao, Hongzhi ^a   Yang, Shufa ⁱ   Guo, Chenyang ^j   Liu, Tianqi ^k   Ma, Kuansheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b HUNAN CANCER HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e GUANGXI MEDICAL UNIVERSITY   (China)

^f THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^g ANHUI PROVINCIAL HOSPITAL   (China)

^h CENTRAL SOUTH UNIVERSITY   (China)

ⁱ XinJiang Tumor Hospital   (China)

^j HENAN CANCER HOSPITAL   (China)

^k People's Hospital   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; TREATMENT DURATION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84925223212     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.343     Document Type: Article

References (34)

1. Jemal A, Ward E, Hao Y et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-9.
2. Bosch FX, Ribes J, Diaz M et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
3. Gomaa AI, Khan SA, Toledano MB et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-8.
4. Venook AP, Papandreou C, Furuse J et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15 ( Suppl 4 ): 5-13.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
6. Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-8.
7. Rossi S, Ravetta V, Rosa L et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology 2010; 53: 136-47.
8. Shi M, Zhang CQ, Zhang YQ et al. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 2004; 28: 376-81.
9. Matsumata T, Kanematsu T, Takenaka K et al. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology 1989; 9: 457-60.
10. Peng ZW, Zhang YJ, Chen MS et al. Radiofrequency ablation withor without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31: 426-32.
11. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
12. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
13. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2 009; 1 0: 2 5-3 4.
14. Liang HY, Lu LG, Hu BS et al. Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas. Chin Med J (Engl) 2013; 126: 4270-6.
15. Li Y, Zheng YB, Zhao W et al. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. Med Oncol 2013; 30: 730.
16. Han G, Yang J, Shao G et al. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol 2013; 9: 403-10.
17. Zhao Y, Wang WJ, Guan S et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol 2013; 24: 1786-92.
18. Wang J, He XD, Yao N et al. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol 2013; 27: 351-63.
19. Zhu AX, Finn RS, Mulcahy M et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2 in patients with advanced hepatocellular cancer. Clin Cancer Res 2013; 19: 6614-23.
20. Eros de Bethlenfalva-Hora C, Mertens JC, Piguet AC et al. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma. Clin Sci (Lond) 2014; 126: 243-52.
21. Fukuda H, Numata K, Moriya S et al. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation-propensity score matching analysis. Radiology 2014; 272: 598-604.
22. Mertens JC, Martin IV, Schmitt J et al. Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. Eur J Radiol 2012; 81: 1601-6.
23. Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol 2010; 15: 242-55.
24. Aussilhou B, Dokmak S, Faivre S et al. Preoperative liver hypertrophy induced by portal fl ow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 2009; 16: 1553-9.
25. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30: 39-50.
26. Chen MSCM. Guidelines for radiofrequency ablation therapy of liver cancer. J Clin Hepatol 2011; 27: 236-44.
27. Pacella CM, Bizzarri G, Anelli V et al. Evaluation of the vascular pattern of hepatocellular carcinoma with dynamic computed tomography and its use in identifying optimal temporal windows for helical computed tomography. Eur Radiol 1998; 8: 30-5.
28. Manini MA, Sangiovanni A, Fornari F et al. Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. J Hepatol 2014; 60: 995-1001.
29. Toshikuni N, Shiroeda H, Ozaki K et al. Advanced ultrasonography technologies to assess the effects of radiofrequency ablation on hepatocellular carcinoma. Radiol Oncol 2013; 47: 224-9.
30. Castellano L, Calandra M, Del Vecchio Blanco C et al. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. J Hepatol 1997; 27: 862-70.
31. Khan KN, Yatsuhashi H, Yamasaki K et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000; 32: 269-78.
32. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal wiThevaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-13.
33. Ishii T, Hatano E, Taura K et al. Sorafenib in a hepatocellular carcinoma patient wiThend-stage renal failure: A pharmacokinetic study. Hepatol Res 2013; 44: 685-8.
34. Bai W, Wang YJ, Zhao Y et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis 2013; 14: 181-90.